Journal
HEMATOLOGICAL ONCOLOGY
Volume -, Issue -, Pages -Publisher
WILEY
DOI: 10.1002/hon.3237
Keywords
CAR T cells; CD19 targeting agents; DLBCL
Categories
Ask authors/readers for more resources
About one third of DLBCL patients experience relapsing/refractory disease after first line chemo-immunotherapy. CAR T cell therapy targeting CD19 is a game changer in the treatment of R/R DLBCL and shows promising results. However, the timing and sequencing of different anti-CD19-targeting therapies and their impact on subsequent CAR T cell treatment is still unclear.
About one third of patients with diffuse large B-cell lymphoma (DLBCL) have a relapsing/refractory (R/R) disease after first line chemo-immunotherapy, with particularly poor outcomes observed in patients with primary refractory disease and early relapse. CD19 specific chimeric antigen receptor (CAR) T cell therapy is a game changer that results in durable and complete response rates in almost half of the patients with R/R DLBCL. Other emerging CD19-targeting therapies include monoclonal antibodies, bispecific antibodies and targeting antibody-drug conjugates, which also show encouraging results. However, the timing and sequencing of different anti-CD19-targeting agents and how they might interfere with subsequent CAR T cell treatment is still unclear. In this review, we summarize the results of the pivotal clinical trials as well as evidence from real-world series of the use of different CD19-targeting approved agents. We discuss the effect of various therapies on CD19 expression and its implications for treatment sequencing.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available